论文部分内容阅读
目的观察依达拉奉对急性脑梗死合并胰岛素抵抗患者肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)水平的影响。方法选择住院治疗急性脑梗死合并胰岛素抵抗患者90例,随机分为两组,每组45例,对照组采用常规治疗,观察组在对照组治疗的基础上加用依达拉奉治疗,同时选10例健康人做健康对照,连续监测血清中TNF-α、IL-6的动态变化;并于治疗后第7、14d进行临床疗效评定。结果两组患者治疗前TNF-α、IL-6水平均高于健康对照组(P<0.05)。观察组患者治疗后第5d TNF-α、IL-6水平恢复至健康对照组水平,对照组患者在治疗后第7d时,TNF-α及IL-6水平均高于观察组患者及健康对照者(P<0.05)。与对照组比较,观察组治疗后第7d、第14d BI评分明显升高、治疗后第14d SSS评分明显降低(P均<0.05);观察组治疗后第14d FINS、HOMA-IR明显改善(P<0.05)。结论急性脑梗死患者合并胰岛素抵抗患者予依达拉奉治疗可降低血清中TNF-α、IL-6水平,降低胰岛素抵抗,改善患者预后。
Objective To observe the effect of edaravone on the levels of tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) in patients with acute cerebral infarction complicated with insulin resistance. Methods Ninety hospitalized patients with acute cerebral infarction and insulin resistance were randomly divided into two groups (n = 45 in each group). The control group received routine treatment. The observation group was treated with edaravone on the basis of the control group. Ten healthy people were healthy controls, and the dynamic changes of TNF-α and IL-6 in serum were monitored continuously. The clinical efficacy was evaluated on the 7th and 14th day after treatment. Results The levels of TNF-α and IL-6 in both groups before treatment were significantly higher than those in healthy controls (P <0.05). The levels of TNF-α and IL-6 in the observation group returned to the level of the healthy control group on the 5th day after treatment, and the levels of TNF-α and IL-6 in the control group were significantly higher than those in the observation group and the healthy control group on the 7th day (P <0.05). Compared with the control group, the score of BI in the observation group on the 7th day and the 14th day significantly increased, and the SSS score decreased significantly on the 14th day after the treatment (all P <0.05). The FINS and HOMA-IR of the observation group were significantly improved on the 14th day after treatment <0.05). Conclusion Edaravone in patients with acute cerebral infarction complicated with insulin resistance can reduce the levels of TNF-α and IL-6 in serum, decrease insulin resistance and improve the prognosis of patients.